Skip to content

Incyte INCY Accounts Payable

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.16B-23.4%
Pfizer logo
PfizerPFE
$4.51B-14.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$10.36M+204%
Gilead Sciences logo
Gilead SciencesGILD
$645M-12.5%
Geron logo
GeronGERN
$12.72M+58.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$10.84M+7.9%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+70.1%
Enterprise value$22.01B+64.9%
P/E16.1×-1.4×
P/S4.5×+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's accounts payable?
Incyte (INCY) reported accounts payable of $250.4M in Q2 2026.
How has Incyte's accounts payable changed year-over-year?
Incyte's accounts payable increased by 3.9% year-over-year, from $241.09M to $250.4M.
What is the long-term trend for Incyte's accounts payable?
Over 5 years (2020 to 2025), Incyte's accounts payable has grown at a 16.3% compound annual growth rate (CAGR), from $98.77M to $209.94M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.